Skip to main content

Advertisement

Table 4 Diagnostic performances of 5 candidate proteins and biomarker panels

From: Novel biomarkers distinguishing pancreatic head Cancer from distal cholangiocarcinoma based on proteomic analysis

Target Positive in PHC Positive in DCC SN SP LR (+) (95% CI) LR (−)(95% CI) P-value
Single marker for PHC diagnosis
 KRT17 55/72 21/74 76.4% 71.6% 2.69 (2.50–2.90) 0.330 (0.299–0.364) 0.0001
 ANXA10 59/72 36/74 81.9% 51.3% 1.68 (1.63–1.72) 0.352 (0.303–0.408) 0.0001
 TMEM109 48/72 27/74 66.7% 63.5% 1.82 (1.72–1.94) 0.525 (0.490–0.563) 0.0003
Single marker for DCC diagnosis
 PTMS 20/72 45/74 60.8% 72.2% 2.19 (2.04–2.35) 0.543 (0.520–0.566) 0.0001
 ATP1B1 30/72 45/74 60.8% 58.3% 1.45 (1.39–1.54) 0.672 (0.635–0.711) 0.031
Panel for PHC diagnosis
 KRT17+/ANXA10+/PTMS- 34/72 6/74 47.2% 91.9% 5.82 (4.18–8.11) 0.574 (0.559–0.590) 0.0001
Panel for DCC diagnosis
 KRT17−/ANXA10−/PTMS+ 2/72 17/74 23.0% 97.2% 8.27 (3.46–19.7) 0.792 (0.786–0.798) 0.0003
  1. PHC Pancreatic head cancer, DCC Distal cholangiocarcinoma, SN Sensitivity, SP Specificity, LR (+) Positive likelihood ratio, LR (−) Negative likelihood ratio, CI Confidence interval